From the Department of Radiology and Research Institute of Radiology (J.H.S., S.H.C., S.Y.K., J.H.B., H.J.W., S.J.L.), and Department of Gastroenterology (Y.S.L.), University of Ulsan College of Medicine, Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, South Korea; Department of Radiology, National Cancer Center, Goyang, South Korea (H.Y.J.).
Radiology. 2019 Aug;292(2):390-397. doi: 10.1148/radiol.2019190035. Epub 2019 Jun 18.
Background The 2017 version of the Liver Imaging Reporting and Data System (LI-RADS) recently included standardized interpretation, reporting, and management guidelines for US (US LI-RADS); however, this system has not yet been validated. Purpose To evaluate the diagnostic performance of US LI-RADS version 2017 for detecting hepatocellular carcinoma (HCC) in participants at high risk and to determine the clinical factors associated with a poor visualization score. Materials and Methods This study included 407 prospectively recruited participants (mean age, 56 years; age range, 28-76 years) with cirrhosis at high risk for HCC who underwent US surveillance from November 2011 to August 2012. Two radiologists retrospectively analyzed US images, assigning a LI-RADS category (US-1 = negative, US-2 = subthreshold, US-3 = positive) and a visualization score (A = no or minimal limitations, B = moderate limitations, C = severe limitations). The sensitivity and specificity for diagnosing HCC were calculated on a per-patient and per-lesion basis, using pathologic results and typical CT or MRI as reference standards. The risk factors for a poor visualization score were determined by using univariable and multivariable analyses. Results Of 429 lesions in 407 participants, there were 32 HCCs in 28 participants. In the per-lesion analysis, the specificity for US-3 was 366 of 397 (92%; 95% confidence interval [CI]: 89%, 95%) and the sensitivity was 11 of 32 (34%; 95% CI: 20%, 52%). In the per-patient analysis, the specificity for US-3 was 352 of 379 (93%; 95% CI: 90%, 95%) and the sensitivity was 11 of 28 (39%; 95% CI: 24%, 58%). Visualization score C (114 of 407 [28%] participants) had the highest false-negative rate (six of seven [86%] participants). High body weight (adjusted odds ratio [OR], 2.1 [95% CI: 1.2, 3.6]; = .01), Child-Pugh class B disease (OR, 2.9 [95% CI: 1.7, 4.9]; < .001), and moderate to severe fatty liver (OR, 1.7 [95% CI: 1.0, 2.8]; = .047) were associated with a poor visualization score of C. Conclusion The US-3 category demonstrated high specificity but low sensitivity for diagnosing hepatocellular carcinoma. The visualization score C had a higher false-negative rate than scores A or B, and patients with high body weight, Child-Pugh class B disease, and moderate to severe fatty liver may present limitations for US surveillance. © RSNA, 2019 See also the editorial by Milot in this issue.
背景 最近,2017 版肝脏影像报告和数据系统(LI-RADS)纳入了用于美国(US LI-RADS)的标准化解读、报告和管理指南;然而,该系统尚未经过验证。目的 评估 2017 版 US LI-RADS 检测高危人群中肝细胞癌(HCC)的诊断性能,并确定与可视化评分较差相关的临床因素。材料与方法 本研究纳入了 407 例经皮肝穿刺活检证实的肝硬化高危患者(平均年龄 56 岁;年龄范围,28-76 岁),这些患者于 2011 年 11 月至 2012 年 8 月期间接受了超声监测。两位放射科医生回顾性地分析了 US 图像,分别为每个病灶分配了一个 LI-RADS 类别(US-1=阴性,US-2=亚阈值,US-3=阳性)和一个可视化评分(A=无或轻微限制,B=中度限制,C=严重限制)。使用病理结果和典型 CT 或 MRI 作为参考标准,分别计算每位患者和每位病灶的 HCC 诊断的敏感度和特异度。使用单变量和多变量分析确定可视化评分较差的风险因素。结果 在 407 例患者的 429 个病灶中,有 32 个病灶在 28 例患者中发现了 HCC。在病灶分析中,US-3 的特异度为 397 个中的 366 个(92%;95%置信区间[CI]:89%,95%),敏感度为 32 个中的 11 个(34%;95% CI:20%,52%)。在患者分析中,US-3 的特异度为 379 个中的 352 个(93%;95% CI:90%,95%),敏感度为 28 个中的 11 个(39%;95% CI:24%,58%)。可视化评分 C(407 例患者中的 114 例[28%])的假阴性率最高(7 例中的 6 例[86%])。高体重指数(调整后的优势比[OR],2.1[95% CI:1.2,3.6]; =.01)、Child-Pugh 分级为 B 级(OR,2.9[95% CI:1.7,4.9]; <.001)和中重度脂肪肝(OR,1.7[95% CI:1.0,2.8]; =.047)与 C 级的较差可视化评分相关。结论 US-3 类别在诊断 HCC 方面具有较高的特异度,但敏感度较低。评分 C 的假阴性率高于评分 A 或 B,体重指数高、Child-Pugh 分级为 B 级和中重度脂肪肝的患者可能会限制 US 监测。